The New England Compounding Center in Framingham, Massachusetts had a license to compound patient-specific prescriptions — the equivalent of what a hospital or specialty pharmacy does at small scale — but from roughly 2006 through 2012 it was operating as a large-scale drug manufacturer, mass-producing thousands of doses without a patient-specific prescription for each one. In 2012, three lots of methylprednisolone acetate compounded at NECC were contaminated with fungus. 798 people got sick. 64 died. The founder and a supervising pharmacist were later convicted of federal crimes. Congress responded with the Drug Quality and Security Act (2013), and Massachusetts responded with Chapter 159 of the Acts of 2014, which created a specialty sterile-compounding license category, restructured the Board of Pharmacy, expanded inspection authority, and enshrined USP <795> and USP <797> standards into state law. The Massachusetts compounding pharmacies that prepare testosterone for Aurafil patients operate under this post-NECC regime.
The 2012 NECC outbreak — the facts
On September 21, 2012, the Tennessee Department of Health notified the CDC that a patient had developed fungal meningitis roughly 19 days after receiving an epidural steroid injection at an ambulatory surgical center. Within a week, cases were reported in six states. By September 25, three lots of preservative-free methylprednisolone acetate from New England Compounding Center in Framingham, MA had been voluntarily recalled. NECC had shipped the contaminated lots to 23 states.
The contaminated drug was methylprednisolone acetate — a corticosteroid, commonly injected into the epidural space for back pain. It was not testosterone. But the lessons for every sterile-compounded injectable — including testosterone cypionate and enanthate — are directly applicable, because the failures at NECC weren't drug-specific. They were failures of sterile technique, environmental monitoring, employee training, and (most fundamentally) failures of the regulatory structure that was supposed to catch them.
What went wrong: manufacturing under a pharmacy license
Compounding pharmacies exist to solve a real clinical problem: some patients need a drug in a strength, dosage form, or preservative-free formulation that isn't commercially available. A physician writes a prescription for that specific patient, and a pharmacy compounds the drug to fill it. This is patient-specific compounding, and it's the model that Section 503A of the federal Food, Drug, and Cosmetic Act was designed to permit — with exemptions from FDA drug-approval and current-good-manufacturing-practice (cGMP) requirements, in exchange for the tighter clinical fit.
NECC held a Massachusetts compounding license under this Section 503A framework. But the FDA investigation that followed the outbreak, and the criminal indictment that followed the investigation, made a specific allegation:
— New England Compounding Center meningitis outbreak, October 2012 findings"An investigation of the NECC revealed the company had been in violation of its state license because it had been functioning as a drug manufacturer, producing drugs for broad use rather than filling individual prescriptions."
In plain English: NECC was licensed as a compounding pharmacy but was operating as a drug manufacturer — producing large lots of methylprednisolone in advance, shipping them out of state, filling standing orders from ambulatory surgery centers, and not always tying doses to specific patient prescriptions. Manufacturers are subject to FDA cGMP, environmental-monitoring, and inspection requirements that compounders are exempt from. NECC took the exemptions but ran the business model those exemptions weren't designed for. When sterile technique failed — insufficient cleaning of clean rooms, autoclave issues, contaminated technicians' garb — no manufacturing-grade quality system caught the failure.
In December 2012, federal prosecutors charged 14 former NECC employees. President Barry Cadden and supervising pharmacist Glenn Chin were convicted at trial; Cadden received a 9-year sentence (later extended); Chin received 8 years. A $200 million victim settlement plan was approved in May 2015.
The federal response: the Drug Quality & Security Act (2013)
Congress passed the Drug Quality and Security Act (H.R. 3204) in November 2013 — one year after the outbreak. Title I, the Compounding Quality Act, restructured federal compounding law in three key ways:
Cleaned up Section 503A
Removed the unconstitutional advertising-restriction language that had cast doubt on 503A's validity, but otherwise kept traditional patient-specific compounding as a state-regulated activity. Compounders operating under 503A are still exempt from FDA cGMP but must fill patient-specific prescriptions.
Created Section 503B "outsourcing facilities"
A new, voluntary category. 503B outsourcing facilities can compound in larger quantities and distribute without patient-specific prescriptions — but they must register with the FDA, comply with cGMP, submit to FDA inspection, and report adverse events. This is the category NECC should have been in (had it existed).
State-federal division kept
State Boards of Pharmacy retain primary regulation of 503A compounders; the FDA has primary authority over 503B facilities. For a Massachusetts patient receiving compounded testosterone, both frameworks matter.
The Massachusetts overhaul: Chapter 159 of the Acts of 2014
Federal action alone wasn't enough for Massachusetts. Governor Deval Patrick convened a Special Commission on the Oversight of Compounding Pharmacies within weeks of the outbreak. The commission's recommendations became Chapter 159 of the Acts of 2014, signed into law in July 2014. It rebuilt Massachusetts compounding oversight from the ground up.
The key provisions:
- New specialty license categories. Massachusetts created dedicated licenses for sterile compounding and non-sterile complex compounding — a compounding pharmacy can no longer operate on a generic pharmacy license. Each specialty carries specific facility, staffing, and quality requirements.
- USP <795> and USP <797> codified. The United States Pharmacopeia's chapters on non-sterile compounding (<795>) and sterile compounding (<797>) — including clean-room specifications, personnel garbing, environmental monitoring, and beyond-use dating — are now enforceable state standards in Massachusetts.
- Board of Pharmacy restructured. At least one of the eight pharmacist members must now have at least 7 years of sterile-compounding experience and be actively engaged in it as a routine job function. The board's inspection and enforcement authority was expanded.
- Trained inspectors. Board of Pharmacy inspectors must now be trained in USP <795> and <797> plus additional sterile and non-sterile compounding surveyor courses. This is a specific response to the NECC finding that inspectors hadn't been trained deeply enough to identify the problems.
- Non-resident licensing. Out-of-state compounding pharmacies that ship into Massachusetts must obtain a Massachusetts non-resident license and comply with the same standards. This closes the "we're in another state so we're not your problem" loophole.
- Compounded-drug labeling. Every compounded drug preparation must now carry a label identifying it as a sterile or non-sterile compounded drug (M.G.L. Ch. 94C §21). Patients receiving a compounded testosterone vial can identify it as compounded on sight.
- Pharmacy Advisory Committee. A permanent advisory committee provides ongoing input to the board on compounding issues.
Post-2014, Massachusetts pharmacists must complete regular continuing education requirements. Pharmacists supervising sterile compounding have specific competency requirements. This was another gap the NECC investigation surfaced — sterile-compounding technique wasn't consistently maintained as a core competency across the workforce.
503A vs. 503B — what patients should actually know
You may hear compounding pharmacies described as "503A" or "503B." Here's the difference in terms that matter for patients.
| 503A (traditional) | 503B (outsourcing facility) | |
|---|---|---|
| Requires patient-specific prescription? | Yes — one prescription, one patient | Not required for each dose |
| Subject to FDA cGMP? | Exempt | Required |
| FDA inspection? | Risk-based; state-primary | Yes — direct FDA oversight |
| State Board of Pharmacy oversight? | Primary | Also |
| Typical use case | Individualized preparations (compounded testosterone at a non-standard concentration, hormone combinations, dose adjustments) | Larger-scale sterile products for hospital and clinic use |
For personalized testosterone therapy, most compounding is done under 503A — because the whole point is patient-specific dose, concentration, and combination. What Chapter 159 of 2014 did was ensure that the state-primary oversight of 503A compounders in Massachusetts operates at a much higher standard than it did pre-2012.
How today's Massachusetts compounding works
A compounded testosterone prescription for an Aurafil patient in Massachusetts today has these safeguards behind it:
- Individual physician MCSR — the prescribing physician holds a current Massachusetts Controlled Substance Registration at a real MA practice address (see our MCSR explainer).
- Facility pharmacy MCSR — the compounding pharmacy holds a current facility MCSR under 105 CMR 700.003, tied to its physical facility.
- Massachusetts sterile-compounding license — the pharmacy holds the specialty sterile-compounding license created by Chapter 159 of 2014, meeting USP <797> clean-room, personnel-garbing, and environmental-monitoring requirements.
- Board-inspected — Massachusetts Board of Pharmacy inspectors trained in USP <795> and <797> conduct routine and for-cause inspections.
- Labeled as compounded — every vial you receive is labeled per M.G.L. Ch. 94C §21 as a compounded sterile drug preparation.
- Reported to MassPAT — every dispensing is reported to the Massachusetts Prescription Awareness Tool within 24 hours (105 CMR 700.012).
- Beyond-use dating — sterile compounded testosterone carries a beyond-use date consistent with USP <797>, not an arbitrary "shelf life."
None of this makes compounded drugs equivalent to FDA-approved commercial products. Compounded drugs are not FDA-approved, and the FDA has been explicit about this since NECC. What Chapter 159 and the DQSA did do is close the specific gaps in oversight that allowed NECC to operate as a manufacturer under a compounding license without anyone catching it in time.
How Aurafil handles this
Our compounding partners are Massachusetts-licensed 503A specialty sterile-compounding pharmacies that opened or fully re-credentialed after Chapter 159 of 2014 took effect. Every pharmacy we work with:
- Holds a current MA specialty sterile-compounding license verifiable on the Board of Pharmacy website
- Holds a current facility MCSR under 105 CMR 700.003
- Maintains USP <797>-compliant clean rooms with documented environmental monitoring
- Employs pharmacists trained specifically in sterile compounding technique
- Provides current inspection records on request
- Sends every prescription with a compounded-drug label and current beyond-use date
We do not use offshore or gray-market suppliers. We do not use "research-use-only" (RUO) suppliers or peptide houses that lack pharmacy licensure. If a compounded product for a specific dosing need isn't available from a properly licensed MA compounder, we default to FDA-approved commercial testosterone (Depo-Testosterone, Xyosted, testosterone cypionate/enanthate from manufacturers registered with FDA) — not a workaround supplier.
Verify our compounding partners
Every Aurafil patient can request the name, MA license number, and facility MCSR of the specific compounding pharmacy that filled their prescription. Both are verifiable on the Massachusetts Board of Pharmacy and DPH websites. We publish this information because Chapter 159 exists — and because the patients most at risk from a Framingham-style incident are the ones who never knew what to look for.
Frequently asked questions
Was testosterone involved in the 2012 NECC outbreak?
No. The contaminated drug was methylprednisolone acetate — a corticosteroid used for epidural pain injections. Testosterone was not one of the drugs implicated. But the failures at NECC (sterile technique, environmental monitoring, staff training, regulatory oversight of the manufacturing-under-compounding-license business model) apply to every sterile-compounded injectable, including testosterone.
Are compounded testosterone products FDA-approved?
No. Compounded drugs — including compounded testosterone — are not FDA-approved. That is a real limitation and we don't understate it. What compounding provides is patient-specific customization (dose, concentration, preservative-free preparations, combination products) that isn't available commercially. When you receive compounded testosterone from a MA-licensed compounder operating under Chapter 159 standards, you're getting a product prepared to USP <797> sterile-compounding requirements, from a facility subject to Board of Pharmacy inspection. That's meaningfully different from a commercially manufactured FDA-approved product, but it's also meaningfully different from what NECC was doing pre-2012.
Does Aurafil ever use FDA-approved (commercial) testosterone instead of compounded?
Yes, when it's clinically appropriate. Commercial testosterone cypionate and enanthate from FDA-approved manufacturers is the default for standard-dose therapy. Compounded testosterone is reserved for individualized dosing needs (non-standard concentrations, larger volumes for split dosing, preservative-free preparations for patients with sensitivities). Your prescribing physician makes this decision with you at the video visit.
How can I verify a Massachusetts compounding pharmacy?
Go to the Massachusetts Board of Registration in Pharmacy portal on mass.gov and search for the pharmacy's name or license number. The record shows current license status, specialty sterile-compounding designation, and any disciplinary actions. Also check that the facility holds a current MCSR — look under the DPH Drug Control Program's public MCSR verification.
What happened to NECC after the outbreak?
NECC declared bankruptcy in December 2012. Its president Barry Cadden was convicted of federal criminal charges in 2017 and sentenced to 9 years (later extended). Supervising pharmacist Glenn Chin was convicted and sentenced to 8 years. A $200 million victim settlement plan was approved in 2015. The facility itself was shut down and never resumed operations.
Could this happen again?
Realistically, no oversight regime is perfect. But the specific failures that made NECC possible — a compounding pharmacy operating as an interstate drug manufacturer without cGMP oversight, inspectors not trained in sterile-compounding technique, no state specialty-license category for sterile compounding, no non-resident licensing for out-of-state compounders shipping in — have all been closed by the combination of the DQSA (2013) and Chapter 159 of the Acts of 2014. If a similar failure were attempted today at a Massachusetts compounder, current inspection and licensing structures are designed to catch it earlier.
Sources
- New England Compounding Center meningitis outbreak — 798 cases, 64 deaths, 20 states, Cadden and Chin convictions.
- CDC — October 2012 NECC outbreak briefing. 23 states received the recalled lots.
- Massachusetts Acts of 2014, Chapter 159 — full text of the post-NECC reform statute.
- Massachusetts Board of Registration in Pharmacy — Oversight of Sterile Compounding, Then and Now. Special Commission and Chapter 159 provisions.
- FDA — Human Drug Compounding Laws. DQSA overview, 503A vs. 503B distinctions.
- National Academies — Regulatory Framework for Compounded Preparations. 503B outsourcing-facility structure.
- Massachusetts General Laws, Chapter 94C, §21 — compounded-drug labeling requirement (as amended by Chapter 159 of 2014).
- 247 CMR 17 — Massachusetts Board of Pharmacy sterile-compounding regulations.
This page is for consumer education. It does not constitute medical or legal advice, does not create a physician-patient relationship, and is not a substitute for individualized evaluation by a licensed physician. Compounded drugs are not FDA-approved, and any decision to use compounded vs. commercial testosterone should be made in consultation with a Massachusetts-licensed prescriber based on your specific clinical needs.